GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Earnings per Share (Diluted)

EQL Pharma AB (FRA:7JK) Earnings per Share (Diluted) : €0.09 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Earnings per Share (Diluted)?

EQL Pharma AB's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.09.

EQL Pharma AB's EPS (Basic) for the three months ended in Mar. 2024 was €0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.09.

EQL Pharma AB's EPS without NRI for the three months ended in Mar. 2024 was €0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €0.09.

During the past 12 months, EQL Pharma AB's average EPS without NRIGrowth Rate was -26.90% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 28.50% per year.

During the past 12 years, EQL Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 123.60% per year. The lowest was -10.80% per year. And the median was 46.70% per year.


EQL Pharma AB Earnings per Share (Diluted) Historical Data

The historical data trend for EQL Pharma AB's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Earnings per Share (Diluted) Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.04 0.10 0.09 0.07

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.03 0.02 0.01

Competitive Comparison of EQL Pharma AB's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's PE Ratio distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's PE Ratio falls into.



EQL Pharma AB Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

EQL Pharma AB's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(2.006-0)/29.796
=0.07

EQL Pharma AB's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0.415-0)/29.796
=0.01

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


EQL Pharma AB  (FRA:7JK) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


EQL Pharma AB Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB (FRA:7JK) Business Description

Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines